Oncotype DX® Recurrence Score® (RS) for 40-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj tamoxifen?
Would you likely order an Oncotype DX® assay for a 40-year-old premenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?
Would you likely recommend that a 40-year-old premenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of tamoxifen without problems (still menstruating) continue or stop tamoxifen therapy?
Biroschak JR et al. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation. Breast J 2013;19(3):269-75. Abstract
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805-16. Abstract
Decreased overall vascular mortality, increased incidence of endometrial cancer in postmenopausal women and reduction in the risk of second breast cancer with 10 versus 5 years of adjuvant tamoxifen. Breast Cancer Update, Issue 1, 2013. Available at: http://www.researchtopractice.com/BCU113/sir-richard-peto/decreased-overall-vascular-mortality-increased-incidence-endometrial-cancer-.
Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013;11(2):174-82. Abstract
Nagaraj G, Ma CX. Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: Challenges and considerations. J Natl Compr Canc Netw 2013;11(3):246-50. Abstract
Results from the ATLAS trial of 5 versus 10 years of adjuvant tamoxifen for women with ER-positive breast cancer. Breast Cancer Update, Issue 1, 2013. Available at: http://www.researchtopractice.com/BCU113/sir-richard-peto/results-atlas-trial-5-versus-10-years-adjuvant-tamoxifen-women-er-positive-b.
Zhu X et al. Systemic treatment decision making for patients with stage I and II, hormone receptor positive, her2/neu negative breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract P3-04-11.